In a Phase 1 combination trial for ...
In a Phase 1 combination trial for Pixantrone (Novuspharma SpA, Bresso Milan, BBR 2778) 58% (11/19) control with relapsed aggressive non-Hodgkin's lymphoma (NHL) achieved an objective rejoinder with an impressive 32% achieving full disappearance of their tumors. In this Phase 1 open-label, dose-escalation trial, the consideration drug was administered in combination with fixed doses of cytarabine, methylprednisolone, and cisplatin (the BSHAP regimen). The primary objective of the meditation was to identify the commended dose of the study mix with drugs to be used in Phase 2 trials. All 19 exposes ...
|